Abstract

Radiation-induced pulmonary fibrosis (RIPF) is a late side effect of thoracic radiotherapy. The purpose of our study was to gain further insight into the development of RIPF. Here, we observed that irradiation of mouse lungs induced collagen deposition, particularly around blood vessels, in the early phase of RIPF. Such deposition subsequently became evident throughout the irradiated tissues. Accompanied by the collagen deposition, vascular EndMT (endothelial-to-mesenchymal transition) began to develop in the early phase of RIPF, before the appearance of EMT (epithelial-to-mesenchymal transition) of alveolar epithelial (AE) II cells in the substantive fibrotic phase. Concomitant with the EndMT, we detected vascular endothelial cell (EC)-specific hypoxic damage in the irradiated lung tissues. In human pulmonary artery endothelial cells (HPAEC), the radiation-induced EndMT via activation of TGFβ-R1/Smad signaling was dependent on HIF1α expression. A novel HIF1α inhibitor, 2-methoxyestradiol (2-ME), inhibited the irradiation-induced EndMT via downregulation of HIF1α-dependent Smad signaling. In vivo, 2-ME inhibited the vascular EndMT, and decreased the collagen deposition associated with RIPF. Furthermore, HIF1α-related EndMT was observed also in human RIPF tissues. We provide the first evidence that an EndMT occurs in RIPF development and that the EndMT may be effectively inhibited by modulating vascular EC-specific hypoxic damage.

Highlights

  • 60% of patients with non–small cell lung cancer receive radiotherapy

  • We provide the first evidence that an EndMT occurs in Radiation-induced pulmonary fibrosis (RIPF) development and that the EndMT may be effectively inhibited by modulating vascular endothelial cell (EC)-specific hypoxic damage

  • Lung sections prepared at various times after irradiation were stained with Masson's trichrome

Read more

Summary

Introduction

60% of patients with non–small cell lung cancer receive radiotherapy. During conventional radiotherapy or stereotactic body radiotherapy, lung complications such as pneumonitis and fibrosis can cause significant morbidity in cancer survivors. Radiation-induced pulmonary fibrosis (RIPF) triggers physiologic abnormalities [1,2,3]. Despite the pressing medical need, little progress has been made to mitigate the radiation-induced pneumonitis. Several medications have been developed to reduce radiation pneumonitis such as. Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.